Mizuho raised the firm’s price target on Cerevel Therapeutics to $45 from $25 and keeps a Neutral rating on the shares. Ahead of Q4 earnings, the firm updated models and revised 12-month price targets in the biotechnology space.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CERE:
- Neurocrine price target raised to $106 from $100 at Piper Sandler
- Neumora Therapeutics appoints Panandiker as Chief Commercial Officer
- Cerevel Therapeutics price target raised to $45 from $25 at JPMorgan
- Karuna downgraded, Arm target raised: Wall Street’s top analyst calls
- Reviva may be most undervalued in neurology, says H.C. Wainwright